[1]. SARTOR O, CASTELLANO GAUNA D E, HERRMANN K, et al. LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)[J/OL]. Annals of Oncology, 2023, 34: S1324-S1325. DOI:10.1016/j.annonc.2023.10.085.
[2]. SARTOR O, DE BONO J, CHI K N, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer[J/OL]. N Engl J Med, 2021, 385(12): 1091-1103.
[3]. K. Herrmann, B. Krause, K. Chi., et al. Tumour dosimetry across 6 cycles of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results from the VISION sub-study.Eur J Nucl Med Mol Imaging (2024) 51 (Suppl 1): S278–S279
[4]. Rosar F, Bader H, Bartholomä M, et al. Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [177Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure-Preliminary Evidence of Pilot Experience. Cancers (Basel). 2022;14(11):2691. Published 2022 May 29.
[5]. Emmett L, Subramaniam S, Crumbaker M, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(5):563-571
[6]. L. Emmett1, M. Swiha1, N. Papa, et al. Dynamic change in tumour PSMA expression between baseline and day 15 after commencing enzalutamide in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901). Eur J Nucl Med Mol Imaging (2024) 51 (Suppl 1): S277–S278.
[7]. A. Giraudet, C. Bailly, P. Barthelemy, et al. Real-life data on [177Lu]Lu-PSMA-617 : Descriptive analysis on the largest RLT metastatic castration-resistant prostate cancer (mCRPC) cohort treated in France.Eur J Nucl Med Mol Imaging (2024) 51 (Suppl 1): S279.